Literature DB >> 30902839

Image-guided volumetric modulated arc therapy (IG-VMAT) for unresectable ACC of the trachea: a feasible curative option.

Rahul Lal Chowdhary1, Kundan Singh Chufal1, Anjali Kakria Pahuja1, Manindra Bhushan1, Rajpal Singh1, Irfan Ahmad1.   

Abstract

A middle-aged man presented with progressively worsening breathlessness and non-productive cough for the last 3 months. On examination, his breathing was stridulous and air entry was decreased bilaterally. He underwent emergency fibre-optic bronchoscopy, which revealed a tracheal growth causing luminal narrowing, and after tumour debulking, he improved symptomatically. Histopathological evaluation of the specimen revealed an adenoid cystic carcinoma of the trachea, and systemic evaluation revealed metastatic dissemination. Systemic molecular-targeted therapy was initiated (gefitinib and later imatinib mesylate) and continued for 5 years, in view of stable disease on periodic follow-up. He subsequently presented with breathlessness again, which was managed with an emergency tracheostomy. In view of stable systemic disease and local progression only, he received definitive radiotherapy with image-guided volumetric modulated arc therapy, which resulted in a complete radiological response. The patient has been disease-free for the last 9 months. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  radiotherapy; respiratory cancer; tyrosine kinase inhibitor

Mesh:

Year:  2019        PMID: 30902839      PMCID: PMC6453438          DOI: 10.1136/bcr-2018-227128

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  45 in total

1.  Low-dose spiral CT: application to surface-rendered three-dimensional imaging of central airways.

Authors:  Yo Won Choi; H Page McAdams; Seok Chol Jeon; Choong Ki Park; Soo-Jin Lee; Bong-Soo Kim; Jong Hyo Kim; Chang Kok Hahm
Journal:  J Comput Assist Tomogr       Date:  2002 May-Jun       Impact factor: 1.826

2.  Unresectable adenoid cystic carcinoma of the trachea treated with chemoradiation.

Authors:  Aaron M Allen; Michael S Rabin; John J Reilly; Steven J Mentzer
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

3.  Occurrence of tracheal carcinoma in Finland.

Authors:  M P Manninen; P J Antila; J S Pukander; P H Karma
Journal:  Acta Otolaryngol       Date:  1991       Impact factor: 1.494

4.  Long-term survival after resection of primary adenoid cystic and squamous cell carcinoma of the trachea and carina.

Authors:  Henning A Gaissert; Hermes C Grillo; M Behgam Shadmehr; Cameron D Wright; Manjusha Gokhale; John C Wain; Douglas J Mathisen
Journal:  Ann Thorac Surg       Date:  2004-12       Impact factor: 4.330

5.  Incidence and treatment of tracheal cancer: a nationwide study in the Netherlands.

Authors:  Jimmie Honings; Jos A A M van Dijck; Ad F T M Verhagen; Henricus F M van der Heijden; Henri A M Marres
Journal:  Ann Surg Oncol       Date:  2006-12-02       Impact factor: 5.344

6.  Radiotherapy for primary carcinoma of the trachea.

Authors:  A Y Cheung
Journal:  Radiother Oncol       Date:  1989-04       Impact factor: 6.280

7.  Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.

Authors:  Mark Agulnik; Ezra W E Cohen; Roger B Cohen; Eric X Chen; Everett E Vokes; Sebastien J Hotte; Eric Winquist; Scott Laurie; D Neil Hayes; Janet E Dancey; Shirley Brown; Gregory R Pond; Ian Lorimer; Manijeh Daneshmand; James Ho; Ming-Sound Tsao; Lillian L Siu
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

Review 8.  Virtual bronchoscopy for evaluation of airway disease.

Authors:  Steven E Finkelstein; Ronald M Summers; Dao M Nguyen; David S Schrump
Journal:  Thorac Surg Clin       Date:  2004-02       Impact factor: 1.750

9.  Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group.

Authors:  J B Vermorken; J Verweij; P H de Mulder; F Cognetti; M Clavel; S Rodenhuis; A Kirkpatrick; G B Snow
Journal:  Ann Oncol       Date:  1993-11       Impact factor: 32.976

10.  Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.

Authors:  Jill Gilbert; Yi Li; Harlan A Pinto; Timothy Jennings; Merrill S Kies; Paula Silverman; Arlene A Forastiere
Journal:  Head Neck       Date:  2006-03       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.